MedTrace Logo

Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)

NCT00441285 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2015-06-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if combination drug therapy of praziquantel and albendazole is safe and effective to cure neurocysticercosis.

Conditions

Interventions

DRUG

Praziquantel

\- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.

DRUG

Albendazole

* Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days. * Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.

DRUG

ABZ Placebo

\- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.

DRUG

PZQ Placebo

\- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Universidad Peruana Cayetano Heredia

    lead OTHER

Principal Investigators

  • Hector H. Garcia, MD · Universidad Peruana Cayetano Heredia

  • E. Javier Pretell, MD · Hospital Alberto

  • Javier A. Bustos, MD · Universidad Peruana Cayetano Heredia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-12-31
Completion
2013-09-30

Countries

  • Peru

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441285 on ClinicalTrials.gov